Interdiziplinäre Notfallsituationen in der Behandlung gynäkologischer Malignome

Kernaussagen

Notfallsituationen bei gynäkologischen Krebserkrankungen entstehen durch die Grunderkrankung selbst, durch Komorbiditäten oder als Nebenwirkung der onkologischen Therapie. Sie führen oftmals in eine lebensbedrohliche Situation, in der rasches Handeln entscheidend für die Prognose ist. Sie manifestieren sich z. B. durch metabolische Entgleisung (ausgeprägte Hyperkalzämie, Tumorlysesyndrom), Einflussstauung, Pleuraerguss, abdominelle Blutungen, kardiale Toxizitäten mancher Chemotherapeutika oder Embolien. Für eine optimale Therapie ist eine interdisziplinäre Betreuung der betroffenen Patientinnen unabdingbar; hier sollte der Gynäkoonkologe je nach Notfallsituation mit Internisten, Intensivmedizinern, Kardiologen oder Kollegen chirurgischer Disziplinen zusammenarbeiten.

• Literatur

• 1 Ralston SH. Pathogenesis and management of cancer associated hypercalcaemia. Cancer Surv 1994; 21: 179-196
• 2 Mundy GR, Bertolini DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986; 13: 291-299
• 3 Alipov GK, Ito M, Nakashima M et al. Expression of parathyroid hormone-related peptide (PTHrP) in gastric tumours. J Pathol 1997; 182: 174-179
• 4 Payne RB, Little AJ, Williams RB et al. Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J 1973; 4: 643-646
• 5 Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002; 29: 12-18
• 6 Klebl F, Krause SW. Akuttherapie onkologischer Notfälle. Intensivmed 2007; 44: 74-87
• 7 Hutcherson DA, Gammon DC, Bhatt MS et al. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006; 26: 242-247
• 8 Parish JM, Marschke jr. RF, Dines DE et al. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 1981; 56: 407-413
• 9 Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol) 2002; 14: 338-351
• 10 Urruticoehea A, Mesia R, Dominguez J et al. Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer. Lung Cancer 2004; 43: 209-214
• 11 Heffner JE. Diagnosis and management of malignant pleural effusions. Respirology 2008; 13: 5-20
• 12 Hentrich M, Hartenstein R. Behandlung maligner Körperhöhlenergüsse. Onkologe 1997; 3: 163-173
• 13 Feller-Kopman D, Berkowitz D, Boiselle P et al. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007; 84: 1656-1661
• 14 Antunes G, Neville E et al. Management of malignant pleural effusions. Thorax 2000; 55: 981-983
• 15 Ried M, Hofmann HS. The treatment of pleural carcinosis with malignant pleural effusion. Dtsch Arztebl Int 2013; 110: 313-318
• 16 Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the art. Eur Respir J 1997; 10: 1648-1654
• 17 Hudson MM, Ness KK, Gurney JG et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013; 309: 2371-2381
• 18 Romond EH, Jeong JH, Rastogi P et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 3792-3799
• 19 Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
• 20 Schlitt A, Jordan K, Vordermark D et al. Cardiotoxicity and oncological treatments. Dtsch Arztebl Int 2014; 111: 161-168
• 21 Cook DJ, Guyatt GH, Salena BJ et al. Endoscopic therapy for acute non-variceal upper gastrointestinal hemorrhage: A meta-analysis. Gastroenterology 1992; 102: 139-148
• 22 Greten H, Jäckle S, Thonke F et al. Endoscopic therapy in non-variceal gastrointestinal bleeding. Dtsch Arztebl 2001; 98: A-604/B-492/C-464
• 23 Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-579
• 24 Sørensen HT, Mellemkjaer L, Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850
• 25 Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907
• 26 Riess H, Pelzer U, Deutschinoff G et al. A prospective, randomized trial of hemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients with advanced pancreatic cancer: Results of the CONKO 004 trial. J Clin Oncol 2009; ASCO Abstract LBA4506. J Clin Oncol 2009; ASCO Abstract LBA4506
• 27 Encke A, Haas S, Sauerland S et al. S3-Leitlinie. Prophylaxe der venösen Thromboembolie (VTE). Vasa 2009; 38: 1-131
• 28 Guyatt GH, Akl EA, Crowther M et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 7S-47S
• 29 Cohen AT, Spiro TE, Spyropoulos AC. MAGELLAN Steering Committee. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 1945-1946
• 30 Clagett GP, Andersen jr. FA, Heit JA et al. Prevention of venous thromboembolism. Chest 1995; 108: 312-334
• 31 Bergqvist D, Agnelli G, Cohen AT et al. ENOXACAN II investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery of cancer. N Engl J Med 2002; 346: 975-980
• 32 van der Hulle T, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: reply. J Thromb Haemost 2014; 12: 2138-2139
• 33 Interdisziplinäre S2-Leitlinie: Lungenembolie (LE). Vasa 2005; 34: 15-24
• 34 Tapson VF. Acute pulmonary embolism. N Engl J Med 2008; 358: 1037-1052
• 35 Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110: 744-749
• 36 Wells PS, Anderson DR, Rodger M et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83: 416-420